Orthotopic Liver Transplantation in an Adult with Cholesterol Ester Storage Disease

Graeme K Ambler • Matthew Hoare • Rebecca Brais •
Ashley Shaw • Andrew Butler • Paul Flynn •
Patrick Deegan • William JH Griffiths

Received: 23 March 2012 / Revised: 02 May 2012 / Accepted: 14 May 2012 / Published online: 24 July 2012
© SSIEM and Springer-Verlag Berlin Heidelberg 2013

Abstract Cholesterol ester storage disease (CESD) is a rare autosomal recessive lipid storage disorder associated with mutations of the gene encoding lysosomal acid lipase, manifestations of which include chronic liver disease and early atherosclerosis. Although normally presenting in childhood, severity is variable and the condition can occasionally remain undetected until middle age. Typical presentation is with asymptomatic hepatosplenomegaly and hyperlipidaemia, though the condition is probably underdiagnosed. Treatment is supportive and may include attention to cardiovascular risk factors. Phase I/II trials of enzyme replacement therapy are ongoing, but this approach

remains experimental. We present the case of a 42-year-old woman diagnosed with CESD in childhood who ran an indolent course until re-presentation with cirrhotic hydrothorax. She underwent orthotopic liver transplantation but required re-transplantation for hepatic artery thrombosis. She remains well with excellent graft function 2 years later. Although atherosclerosis was apparent at assessment, and may have contributed to hepatic artery thrombosis, partial correction of the metabolic defect and restoration of liver function by transplantation together with ongoing medical therapy should permit reasonable survival over the longer term from both a liver and a vascular perspective. This is the first reported case of orthotopic liver transplantation for CESD in an adult, which was the only available option to improve survival. The case highlights the importance of monitoring patients with CESD through adulthood and suggests that liver replacement at a later stage may yet be indicated and remain of benefit.

Communicated by: Frits Wijburg

Competing interests: None declared

G.K. Ambler (✉) • A. Butler
Department of Surgery, Cambridge University Hospitals,
Hills Road, Cambridge, CB2 0QQ, UK
e-mail: graeme.ambler@addenbrookes.nhs.uk

M. Hoare • W.J.H. Griffiths
Department of Hepatology, Cambridge University Hospitals,
Cambridge, UK

M. Hoare • P. Flynn • P. Deegan
Department of Medicine, Cambridge University Hospitals,
Cambridge, UK

R. Brais
Department of Pathology, Cambridge University Hospitals,
Cambridge, UK

A. Shaw
Department of Radiology, Cambridge University Hospitals,
Cambridge, UK

Introduction

Cholesterol ester storage disease (CESD) is a rare autosomal recessive lipid storage disorder caused by lysosomal acid lipase (LAL) deficiency; this results in chronic liver disease. LAL is responsible for lysosomal cleavage of ester bonds in a range of lipids, including cholesterol esters and triglycerides. Thus, lack of LAL activity leads to intralysosomal accumulation of lipid (Anderson et al. 1993). In humans, LAL is encoded by the LIPA gene located on chromosome 10. Complete loss-of-function mutations in LIPA lead to development of Wolman's disease; this presents in infancy with failure to thrive and is usually fatal before the age of 6 months (Anderson and Sando 1991). CESD arises from hypomorphic mutations in the

Table 1 Fasting lipid profile of a 42-year-old woman with CESD over 3 years from pregnancy through to recent liver transplantation. Statin therapy was commenced post-partum which improved LDL but not HDL cholesterol. The latter improved following liver transplantation

	Pregnancy	Pre-transplant	Post-transplant	Current
Cholesterol (mmol/L)	5.7	3.0	4.1	2.9
Triglyceride (mmol/L)	1.4	1.0	1.7	0.6
HDL cholesterol (mmol/L)	0.93	0.35	1.00	1.13
LDL cholesterol (mmol/L)	4.17	2.25	2.40	1.57

LIPA gene, which impair either expression or function of LAL. The majority of patients described to date possess a homozygous G to A substitution at location -1 of the splice donor site of exon 8 of LIPA (c.894G>A), which causes deletion of exon 8 and production of only 2–4 % normal enzyme (Muntoni et al. 2007). Heterozygote carrier frequencies have been estimated at 1 in 200 in northern Europe. However, genotypic heterogeneity is evident from reported compound heterozygotes with CESD (Muntoni et al. 2007; Pisciotta et al. 2009).

CESD usually presents in childhood or adolescence with hypercholesterolemia or hepatomegaly due to hepatic steatosis that eventually progresses to cirrhosis (Chatrath et al. 2009). Patients may succumb to complications relating to accelerated atherosclerosis or chronic liver disease, including hepatocellular carcinoma. Historically, most patients known to have CESD died before the age of 30 years (Leone et al. 1991; McCoy and Yokoyama 1991). However, it is increasingly recognised that milder forms of CESD can occur, raising questions regarding the true natural history of this disorder.

Case History

A 42-year-old woman with a known history of CESD presented with a 1-week history of progressive dyspnoea following administration of the H1N1 influenza vaccination. This was accompanied by more gradual abdominal distension. The patient had originally come to medical attention at the age of 6 years with hepatosplenomegaly, whereby CESD was diagnosed following liver biopsy. She defaulted from follow-up and remained well into adulthood. At the age of 39 years, she sought further specialist review during pregnancy. Leukocyte acid esterase (i.e. leukocyte LAL) activity was low at 93 $\mu\text{mol/g/h}$ (350–2000) with an elevated plasma chitotriosidase activity of 222 $\mu\text{mol/L/}$

h (4–120), reaffirming the diagnosis. Lipid profile after overnight fasting demonstrated cholesterol 5.7 mmol/L, triglyceride 1.4 mmol/L, HDL-C 0.93 mmol/L and LDL-C 4.17 mmol/L (Table 1). Pregnancy was uneventful and statin therapy was commenced post-partum. She defaulted from specialist follow-up, though continued statin therapy.

No additional risk factors for chronic liver disease could be elicited at time of admission. Examination and chest radiography demonstrated the presence of a moderate right pleural effusion. Laboratory values were as follows: serum bilirubin 45 $\mu\text{mol/L}$ (<17), prothrombin time (PT) 16.2 s (9.8–12.6), serum creatinine 57 $\mu\text{mol/L}$ (35–125), serum sodium 138 mmol/L (135–145) and urine sodium <5 mmol/L. Her Model of End-Stage Liver Disease score was 14 (Kamath et al. 2001), and United Kingdom End-Stage Liver Disease (UKELD) score 50.1 (Lewsey et al. 2006).

Pleural aspiration revealed a transudative effusion consistent with cirrhotic hydrothorax. Abdominal ultrasonography (US) demonstrated an enlarged nodular liver with patent portal and hepatic veins, gross ascites and 22 cm splenomegaly. Diuretics did not eliminate the requirement for regular thoracentesis and a transjugular intrahepatic portosystemic shunt was felt unlikely to improve survival. Patients with end-stage liver disease and a UKELD score greater than 49 have previously been shown to benefit from liver transplantation in terms of their predicted survival at 1 year (Barber et al. 2007), so this together with the patient's diuretic resistant ascites led us to proceed with a formal liver transplant assessment.

Computed tomography (CT) confirmed the previous findings at US (Fig. 1, panel a). Multiple high-density calcified nodules were also noted. Further, there was significant calcification of the descending aorta and aortic arch (Fig. 1, panels b and c). Transthoracic echocardiography demonstrated mild left ventricular diastolic dysfunction but was otherwise normal; 9 min of exercise treadmill testing were completed without electrocardiographic changes. Psychiatric evaluation was satisfactory and the patient was listed for liver transplantation on the grounds of the accepted indication of diuretic-resistant ascites in the form of hydrothorax, further supported by a UKELD score greater than 49.

At operation, a mildly fatty, deceased donor allograft was implanted using duct-to-duct biliary anastomosis and cavo-cavoplasty; an infra-renal aortic conduit was fashioned as initial arterial inflow was impaired. Cold and warm ischaemic times were 9 h 10 min and 36 min, respectively. Standard post-operative immunosuppression with prednisolone, azathioprine and tacrolimus was administered. Explant histology showed cirrhosis and was consistent with the diagnosis of CESD. Numerous lipid-laden macrophages and Kupffer cells were present within sinusoids that were CD68 positive and diastase periodic acid Schiff resistant (Fig. 2). No additional form of chronic liver disease was apparent.

Fig. 1 CT images of a 42-year-old woman with end-stage liver disease due to CESD. Imaging obtained prior to liver transplantation. Post-contrast axial CT image of the upper abdomen showing a nodular liver containing multiple tiny foci of calcification in association with

splenomegaly, ascites and a moderate right pleural effusion (a). Non-contrast sagittal CT images of the major arteries showing extensive calcification in the abdominal and thoracic aorta (b and c, respectively)

Initial recovery post transplantation was complicated by an episode of acute cellular rejection that resolved with intravenous methyl-prednisolone and the patient was discharged home 3 weeks following transplantation. Repeat enzyme analysis at discharge showed normalisation of plasma chitotriosidase activity ($42 \mu\text{mol/L/h}$) and persistent leukocyte acid esterase deficiency ($39 \mu\text{mol/g/h}$). Repeated fasting lipid profile revealed a significant rise in HDL cholesterol (Table 1).

Ten weeks post-transplant, during investigation for asymptomatic deranged liver function tests, imaging revealed unexpected hepatic artery thrombosis. Following clinical deterioration, the patient was subsequently re-listed and received a second transplant 3 months following her initial graft. Explant histology revealed an ischaemic liver with organised thrombus of the hepatic artery at the hilum. The thrombosed arterial conduit was left in situ and not examined histologically. Subsequent progress has been uncomplicated; the patient was formally anticoagulated with low-molecular-weight heparin for 3 months following re-transplant to reduce the risk of further hepatic artery thrombosis and is currently well on aspirin and statin therapy with excellent graft function almost 2 years following her second transplant.

In order to further characterise this patient's disorder, sequencing of LIPA was performed (Fig. 3). This revealed compound heterozygosity: c.[894G>A];[599T>C] (the common c.894G>A substitution described above and a T to C substitution at location 599 causing leucine to proline substitution). The second mutation is thought to disrupt alpha helical structure (Anderson et al. 1994). This compound heterozygous combination has been previously reported in siblings with CESD (Maslen et al. 1995).

Discussion

We have presented the first report of an adult liver transplantation for CESD. Our subject developed diuretic-resistant ascites with hydrothorax at the age of 42 years, having been diagnosed in childhood and run an indolent course during early adulthood. CESD has been previously diagnosed de novo in adulthood: Elleder et al. (1990) described CESD in two women aged 43 and 56 years, respectively, both of whom had asymptomatic hepatomegaly. One of these patients subsequently died of cerebrovascular disease. The same group subsequently described a 51-year-old man with a long-standing history of dyslipidaemia who died of cholangiocarcinoma (Elleder et al. 2000a). Autopsy findings demonstrated hepatomegaly with micronodular cirrhosis and disseminated cholangiocarcinoma; extensive severe atherosclerosis was also observed (Elleder et al. 2000b). Chatrath et al. (2009) reported a 43-year-old man diagnosed with CESD on liver biopsy performed with a view to staging hepatitis C infection. Further, they summarised the features of an additional 18 cases previously described. Reported deaths were either due to vascular disease or hepatic disease (liver failure or hepatobiliary malignancy).

No drug therapy exists for this condition, although normalisation of lipid profiles using cholestyramine or HMG-CoA reductase inhibitors has been reported (Leone et al. 1991; McCoy and Yokoyama 1991). Normalisation of the lipid profile does not necessarily prevent progression to hepatic failure in CESD, however, as seen in the case reported by Leone et al. (1995). Enzyme replacement therapy has shown promise in reducing lipid deposition in peripheral tissues in mouse and rat models of complete LAL deficiency analogous to Wolman's disease and is now

Fig. 2 Liver explant histology following transplantation for end-stage liver disease due to CESD. Chromotrope Aniline Blue staining (a) demonstrating established cirrhosis with complete nodules surrounded by broad fibrous septae (x40). Haematoxylin and Eosin (H&E)-stained section (b) demonstrating numerous foamy macrophages with tan-coloured cytoplasm within residual portal areas and fibrous septae

(x200). H&E stained section (c) demonstrating lipid-laden, foamy hypertrophic Kupffer cells and sinusoidal macrophages (arrow) (x400). CD68 staining (d) showing strong positivity for intrasinusoidal macrophages and Kupffer cells (x400) which are periodic acid Schiff positive and diastase resistant (e) (x400)

being examined in phase I/II clinical trials for patients with CESD (Du et al. 2008; Enns 2012). Although this is not currently routine treatment and is unlikely to be of significant benefit once irreversible liver damage has occurred, this is an important research area, as is detection of CESD in adults with abnormal liver function.

Although successful liver transplantation for CESD has previously been reported in children and young adolescents (Arterburn et al. 1991; Ferry et al. 1991; Leone et al. 1995), this patient is far older than any of the previously reported cases. As a result of the increased cardiovascular mortality seen in CESD, and given that the patient had been untreated for the vast majority of her life, a major concern was the

degree of established atherosclerosis and associated cardiovascular risk present. Although our patient had no overt signs of vascular disease, CT imaging had revealed extensive aortic calcification (Fig. 1). Furthermore, Doppler ultrasound imaging of the carotid arteries revealed dense plaques associated with mild stenoses. These findings of established atherosclerosis would be in keeping with her known CESD and may have been a factor in the development of post-transplant hepatic artery thrombosis; arterial anastomosis is technically more challenging in the presence of calcified atherosclerotic plaques, and plaque rupture around the site of anastomosis can occur. Despite these findings, we felt that there remained a clear benefit for liver transplantation.

Fig. 3 DNA sequence chromatograms of a section of the *LIPA* gene from a 42-year-old woman with CESD. The grey boxes highlight heterozygous substitutions found in both forward and reverse directions at locations 599 (*top*, C substituted for wild-type T) and 894 (*bottom*, A

substituted for wild-type G). The former is thought to result in disruption of alpha-helical structure, while the latter is found at a splice junction and usually causes deletion of exon 8, resulting in less than 10 % expression of normal protein (r.[894g>t,822_894delinsu])

Initial fasting lipid profiling demonstrated hypercholesterolemia with low HDL cholesterol (Table 1). Although statin therapy led to a reduction in total cholesterol, the low HDL cholesterol reversed only following liver transplantation. Multiple studies in healthy subjects have demonstrated the predictive importance of low HDL cholesterol in future cardiac and cerebrovascular outcome (Natarajan et al. 2010). Indeed a recent consensus statement on defining the metabolic syndrome has used a cut-off of less than 1.3 mmol/L as abnormal in a female population (Alberti et al. 2009). Normalisation of HDL cholesterol levels in CESD following commencement of HMG-CoA reductase inhibitors has previously been reported in pre-cirrhotic cases in the paediatric population (Leone et al. 1991), so it is likely that the low HDL cholesterol level observed here was related to impaired liver synthetic function. Liver transplantation may therefore be effective in reducing long-term vascular risk although this may be counterbalanced by the side effects of calcineurin inhibitors and the ongoing peripheral defect as evidenced by persistent leukocyte acid esterase deficiency.

In summary, we present the first published case of successful liver transplantation in an adult with CESD. The report highlights the challenges of concomitant vascular disease and the potential indolent nature of CESD in adulthood. The patient described here was lost to follow-up

twice before presenting with severe decompensated liver disease. Our case therefore also emphasises the need for educating patients with asymptomatic but potentially progressive liver disease and for continued awareness amongst clinicians overseeing adult metabolic disorders. Two years following transplantation, the patient has remained free of vascular events, with excellent liver function and a normal lipid profile. Liver transplantation for CESD may therefore yield a significant survival advantage even well into adulthood. There is little evidence to support liver replacement other than in the context of liver failure. We can only speculate as to whether pre-emptive liver transplantation might ameliorate the mortality associated with vascular disease in CESD, particularly if HMG-CoA reductase inhibition might already offset this. Liver transplantation is therefore a viable option for adults with liver failure related to CESD; close monitoring of patients with CESD and liaison with tertiary hepatology services are important for the optimal timing of this intervention.

Synopsis

Regular follow-up of liver function in adults with cholesterol ester storage disease, an uncommon lipid storage

disorder, is an important consideration as orthotopic liver transplantation may be required to maintain long-term survival.

Conflicts of Interest and Financial Disclosures

The authors would like to thank Synageva Biopharma Corporation for providing the chromatograms in Fig. 3.

References

- Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. *Circulation* 120:1640–1645
- Anderson RA, Byrum RS, Coates PM et al (1994) Mutations at the lysosomal acid cholesteryl ester hydrolase gene locus in Wolman disease. *Proc Natl Acad Sci USA* 91:2718–2722
- Anderson RA, Rao N, Byrum RS et al (1993) In situ localization of the genetic locus encoding the lysosomal acid lipase/cholesteryl esterase (LIPA) deficient in Wolman disease to chromosome 10q23.2-q23.3. *Genomics* 15:245–247
- Anderson RA, Sando GN (1991) Cloning and expression of cDNA encoding human lysosomal acid lipase/cholesteryl ester hydrolase. Similarities to gastric and lingual lipases. *J Biol Chem* 266:22479–22484
- Arterburn JN, Lee WM, Wood RP et al (1991) Orthotopic liver transplantation for cholesteryl ester storage disease. *J Clin Gastroenterol* 13:482–485
- Barber KM, Pioli SE, Blackwell JE et al (2007) Development of a UK score for patients with end-stage liver disease. *Hepatology* 46:510A
- Chatrath H, Keilin S, Attar BM (2009) Cholesterol ester storage disease (CESD) diagnosed in an asymptomatic adult. *Dig Dis Sci* 54:168–173
- Du H, Cameron TL, Garger SJ et al (2008) Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in mice. *J Lipid Res* 49:1646–1657
- Elleder M, Chlumska A, Hyanek J et al (2000a) Subclinical course of cholesteryl ester storage disease in an adult with hypercholesterolemia, accelerated atherosclerosis, and liver cancer. *J Hepatol* 32:528–534
- Elleder M, Chlumska A, Ledvinova J et al (2000b) Testis - a novel storage site in human cholesteryl ester storage disease. Autopsy report of an adult case with a long-standing subclinical course complicated by accelerated atherosclerosis and liver carcinoma. *Virchows Arch* 436:82–87
- Elleder M, Ledvinova J, Cieslar P et al (1990) Subclinical course of cholesterol ester storage disease (CESD) diagnosed in adulthood. Report on two cases with remarks on the nature of the liver storage process. *Virchows Arch A* 416:357–365
- Enns G (2012) Initial human experience with sbc-102, a recombinant enzyme replacement therapy in adults with lysosomal acid lipase deficiency. Presented at the 8th Annual Lysosomal Disease Network (LDN) World Symposium
- Ferry GD, Whisennand HH, Finegold MJ et al (1991) Liver transplantation for cholesteryl ester storage disease. *J Pediatr Gastroenterol Nutr* 12:376–378
- Kamath PS, Wiesner RH, Malinchoc M et al (2001) A model to predict survival in patients with end-stage liver disease. *Hepatology* 33:464–470
- Leone L, Ippoliti PF, Antonicelli R (1991) Use of simvastatin plus cholestyramine in the treatment of lysosomal acid lipase deficiency. *J Pediatr* 119:1008–1009
- Leone L, Ippoliti PF, Antonicelli R et al (1995) Treatment and liver transplantation for cholesterol ester storage disease. *J Pediatr* 127:509–510
- Lewsey JD, Dawwas M, Copley LP et al (2006) Developing a prognostic model for 90-day mortality after liver transplantation based on pretransplant recipient factors. *Transplantation* 82:898–907
- Maslen CL, Babcock D, Illingworth DR (1995) Occurrence of a mutation associated with Wolman disease in a family with cholesteryl ester storage disease. *J Inherit Metab Dis* 18:620–623
- McCoy E, Yokoyama S (1991) Treatment of cholesteryl ester storage disease with combined cholestyramine and lovastatin. *Ann NY Acad Sci* 623:453–454
- Muntoni S, Wiebusch H, Jansen-Rust M et al (2007) Prevalence of cholesteryl ester storage disease. *Arterioscler Thromb Vasc Biol* 27:1866–1868
- Natarajan P, Ray KK, Cannon CP (2010) High-density lipoprotein and coronary heart disease: current and future therapies. *J Am Coll Cardiol* 55:1283–1299
- Pisciotta L, Fresa R, Bellocchio A et al (2009) Cholesteryl Ester Storage Disease (CESD) due to novel mutations in the LIPA gene. *Mol Genet Metab* 97:143–148